Filip Janku

Filip Janku

UNVERIFIED PROFILE

Are you Filip Janku?   Register this Author

Register author
Filip Janku

Filip Janku

Publications by authors named "Filip Janku"

Are you Filip Janku?   Register this Author

100Publications

3862Reads

28Profile Views

Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.

Lancet Gastroenterol Hepatol 2019 Sep 9;4(9):711-720. Epub 2019 Jul 9.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2468-1253(19)30189-XDOI Listing
September 2019

TAK228 enhances antitumor activity of eribulin in triple negative breast cancer.

Oncotarget 2019 Aug 20;10(49):5011-5019. Epub 2019 Aug 20.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.27082DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6707945PMC
August 2019

Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis.

Mol Cancer Ther 2019 06 23;18(6):1149-1157. Epub 2019 Apr 23.

Center for Personalized Cancer Therapy, Division of Blood and Marrow Transplantation, Division of Hematology/Oncology, Department of Medicine, University of California San Diego, Moores Cancer Center, La Jolla, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-18-1244DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548628PMC
June 2019

Liquid Biopsies Using Plasma Exosomal Nucleic Acids.

Oncoscience 2019 Mar 1;6(3-4):296-297. Epub 2019 Apr 1.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncoscience.478DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6508195PMC
March 2019

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018).

Authors:
Sneha Berry Nicolas Giraldo Peter Nguyen Benjamin Green Haiying Xu Aleksandra Ogurtsova Abha Soni Farah Succaria Daphne Wang Charles Roberts Julie Stein Elizabeth Engle Drew Pardoll Robert Anders Tricia Cottrell Janis M Taube Ben Tran Mark Voskoboynik James Kuo Yung-Lue Bang Hyun-Cheo Chung Myung-Ju Ahn Sang-We Kim Ayesh Perera Daniel Freeman Ikbel Achour Raffaella Faggioni Feng Xiao Charles Ferte Charlotte Lemech Funda Meric-Bernstam Theresa Werner Stephen Hodi Wells Messersmith Nancy Lewis Craig Talluto Mirek Dostalek Aiyang Tao Sarah McWhirter Damian Trujillo Jason Luke Chunxiao Xu BoMarelli Jin Qi Guozhong Qin Huakui Yu Molly Jenkins Kin-Ming Lo Joern-Peter Halle Yan Lan Matthew Taylor Nicholas Vogelzang Allen Cohn Daniel Stepan Robert Shumaker Corina Dutcus Matthew Guo Emmett Schmidt Drew Rasco Marcia Brose Nicholas Vogelzang Christopher Di Simone Sharad Jain Donald Richards Carlos Encarnacion Drew Rasco Robert Shumaker Corina Dutcus Daniel Stepan Matthew Guo Emmett Schmidt Matthew Taylor Nicholas Vogelzang Carlos Encarnacion Allen Cohn Christopher Di Simone Drew Rasco Donald Richards Matthew Taylor Corina Dutcus Daniel Stepan Robert Shumaker Matthew Guo Emmett Schmidt James Mier Jeongshin An Yeun-Yeoul Yang Won-Hee Lee Jinho Yang Jong-Kyu Kim Hyun Goo Kim Se Hyun Paek Jun Woo Lee Joohyun Woo Jong Bin Kim Hyungju Kwon Woosung Lim Nam Sun Paik Yoon-Keun Kim Byung-In Moon Filip Janku David Tan Juan Martin-Liberal Shunji Takahashi Ravit Geva Ayca Gucalp Xueying Chen Kulandayan Subramanian Jennifer Mataraza Jennifer Wheler Philippe Bedard

J Immunother Cancer 2019 Feb 13;7(1):46. Epub 2019 Feb 13.

Princess Margaret Cancer Centre, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0519-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373015PMC
February 2019

Moving Precision Oncology Forward Amid Myths and Misconceptions.

JAMA Oncol 2018 12;4(12):1788-1789

Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2018.5064DOI Listing
December 2018

A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement.

Cancer Chemother Pharmacol 2018 11 4;82(5):877-885. Epub 2018 Sep 4.

Department of Investigational Cancer Therapeutics, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-018-3680-yDOI Listing
November 2018

Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic.

Oncotarget 2018 Sep 4;9(69):33232-33243. Epub 2018 Sep 4.

Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26075DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145698PMC
September 2018

BRAF alterations in primary brain tumors.

Discov Med 2018 08;26(141):51-60

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
August 2018

Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers.

Mol Cancer Ther 2018 07 13;17(7):1595-1601. Epub 2018 Apr 13.

Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-17-1107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310221PMC
July 2018

Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.

J Clin Oncol 2018 05 5;36(13):1291-1299. Epub 2018 Feb 5.

Dejan Juric, Massachusetts General Hospital Cancer Center, Boston; Alan Huang, Novartis Institutes for BioMedical Research, Cambridge, MA; Jordi Rodon and Josep Tabernero, Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona; Marta Gil-Martin, Catalan Institute of Oncology - Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain; Filip Janku, The University of Texas MD Anderson Cancer Center, Houston, TX; Howard A. Burris, Sarah Cannon Research Institute and Tennessee Oncology; Jordan Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, the Netherlands; Mark R. Middleton, National Institute for Health Research, Oxford Biomedical Research Centre, Churchill Hospital, Oxford, United Kingdom; Martin Schuler, West German Cancer Center, University Duisburg-Essen, and German Cancer Consortium, Partner Site University Hospital Essen, Essen; Ruth Seggewiss-Bernhardt, Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany; Hope S. Rugo, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Douglas Bootle, David Demanse, Lars Blumenstein, and Cornelia Quadt, Novartis Pharma AG, Basel, Switzerland; Christina Coughlin, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.72.7107
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.72.7107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920739PMC
May 2018

Targeting the PI3K pathway in cancer: are we making headway?

Nat Rev Clin Oncol 2018 05 6;15(5):273-291. Epub 2018 Mar 6.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/doifinder/10.1038/nrclinonc.2018.28
Publisher Site
http://dx.doi.org/10.1038/nrclinonc.2018.28DOI Listing
May 2018

Advances on the BRAF Front in Colorectal Cancer.

Authors:
Filip Janku

Cancer Discov 2018 04;8(4):389-391

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-18-0125DOI Listing
April 2018

Circulating tumor DNA-From bench to bedside.

Curr Probl Cancer 2017 May - Jun;41(3):212-221. Epub 2017 Mar 1.

Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01470272173002
Publisher Site
http://dx.doi.org/10.1016/j.currproblcancer.2017.02.005DOI Listing
March 2018

Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers.

Mol Cancer Ther 2018 03 13;17(3):671-676. Epub 2017 Dec 13.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-17-0673DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935561PMC
March 2018

Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.

J Immunother Cancer 2017 12 19;5(1):100. Epub 2017 Dec 19.

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Unit 455, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-017-0301-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735899PMC
December 2017

Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.

Invest New Drugs 2017 10 13;35(5):616-626. Epub 2017 Feb 13.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-017-0442-3
Publisher Site
http://dx.doi.org/10.1007/s10637-017-0442-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935457PMC
October 2017

Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients.

Authors:
Filip Janku

Cancer Treat Rev 2017 Sep 18;59:93-101. Epub 2017 Jul 18.

MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Houston, TX, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.07.005DOI Listing
September 2017

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.

Breast Cancer Res 2017 Aug 15;19(1):93. Epub 2017 Aug 15.

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-017-0878-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557476PMC
August 2017

Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape.

Oncoscience 2017 May 23;4(5-6):47-56. Epub 2017 Jun 23.

Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncoscience.352DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538848PMC
May 2017

Metastatic Adenoid Cystic Carcinoma Mimicking Butterfly Glioblastoma: A Rare Presentation in the Splenium of the Corpus Callosum.

World Neurosurg 2016 Nov 10;95:621.e13-621.e19. Epub 2016 Aug 10.

Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2016.07.111DOI Listing
November 2016

Bringing Blood-Based Molecular Testing to the Clinic.

Clin Cancer Res 2016 Nov 23;22(22):5400-5402. Epub 2016 Sep 23.

Center for Personalized Cancer Therapy, Moores Cancer Center, The University of California San Diego, La Jolla, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-1769DOI Listing
November 2016

Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?

Expert Rev Mol Diagn 2015 11;15(12):1631-44. Epub 2015 Nov 11.

c Department of Biology, Faculty of Medicine in Plzen , Charles University in Prague , Plzen , Czech Republic.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737159.2015.1110021DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016094PMC
September 2016

Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials.

Cancer Chemother Pharmacol 2016 07 10;78(1):167-71. Epub 2016 Jun 10.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 455, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-016-3073-zDOI Listing
July 2016

Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer.

J Clin Oncol 2016 05 4;34(15):1764-71. Epub 2016 Apr 4.

David Hong, Filip Janku, Ly M. Nguyen, Aung Naing, Sarina Piha-Paul, Faye M. Johnson, and Razelle Kurzrock, The University of Texas MD Anderson Cancer Center, Houston, TX; Jeffrey Infante, Suzanne Jones, Howard Burris, Todd M. Bauer, and Johanna Bendell, Sarah Cannon Research Institute; Jeffrey Infante, Howard Burris, Todd M. Bauer, and Johanna Bendell, Tennessee Oncology, Nashville, TN; and Lisa Golden, Scott Hynes, Ji Lin, and Aimee Bence Lin, Eli Lilly, Indianapolis, IN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.5788DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321045PMC
May 2016

Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer.

Cancer Chemother Pharmacol 2016 05 16;77(5):1097-102. Epub 2016 Apr 16.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-016-3000-3DOI Listing
May 2016

Targeting isocitrate dehydrogenase (IDH) in cancer.

Discov Med 2016 05;21(117):373-80

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://tatcongress.org/wp-content/uploads/2015/03/O11.3-Step
Web Search
May 2016

Cell-free DNA as a novel marker in cancer therapy.

Biomark Med 2015 ;9(7):703-12

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, FC8.2018, Box 0455, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/bmm.15.38DOI Listing
April 2016

Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm.

Mol Cancer Ther 2016 04 23;15(4):533-47. Epub 2016 Mar 23.

Center for Personalized Cancer Therapy, Moores Cancer Center, University of California, San Diego, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-15-0643DOI Listing
April 2016

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.

J Clin Oncol 2015 Dec 12;33(34):4032-8. Epub 2015 Oct 12.

Scott Kopetz, Dipen Maru, Van Morris, Filip Janku, and Arvind Dasari, The University of Texas MD Anderson Cancer Center, Houston, TX; Emily Chan, Vanderbilt-Ingram Cancer Center, Nashville, TN; Joel Randolph Hecht, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles; Brian James and Garth Powis, Sanford Burnham Institute, La Jolla; Keith B. Nolop, Plexxikon, Berkeley; Suman Bhattacharya, Genentech, South San Francisco, CA; Peter J. O'Dwyer, Abramson Cancer Center at University of Pennsylvania, Philadelphia, PA; Woonbook Chung and Jean-Pierre J. Issa, Fels Institute for Cancer Research and Molecular Biology, Temple University, Philadelphia, PA; Leonard Saltz, Memorial Sloan-Kettering Cancer Center, New York, NY; and Jayesh Desai and Peter Gibbs, Royal Melbourne Hospital, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/10/12/JCO.2015.63
Web Search
http://jco.ascopubs.org/content/suppl/2015/11/23/33.34.4032.
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.63.2497
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.63.2497DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669589PMC
December 2015

Accessing Genetic Information with Liquid Biopsies.

Trends Genet 2015 Oct;31(10):564-575

Oncology, Illumina, Inc., 5200 Illumina Way, San Diego, CA 92122, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tig.2015.06.001DOI Listing
October 2015

Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver.

Invest New Drugs 2015 Aug 21;33(4):911-20. Epub 2015 May 21.

Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-015-0251-5
Publisher Site
http://dx.doi.org/10.1007/s10637-015-0251-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492845PMC
August 2015

The mu opioid receptor: A new target for cancer therapy?

Cancer 2015 Aug 4;121(16):2681-8. Epub 2015 Jun 4.

Division of Cancer Medicine, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29460DOI Listing
August 2015

Challenges and perspective of drug repurposing strategies in early phase clinical trials.

Oncoscience 2015 30;2(6):576-80. Epub 2015 Jun 30.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506360PMC
http://dx.doi.org/10.18632/oncoscience.173DOI Listing
August 2015

Multiple gene aberrations and breast cancer: lessons from super-responders.

BMC Cancer 2015 May 29;15:442. Epub 2015 May 29.

Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California at San Diego Moores Cancer Center, La Jolla, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-015-1439-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4446801PMC
May 2015

HER2/neu-directed therapy for biliary tract cancer.

J Hematol Oncol 2015 May 29;8:58. Epub 2015 May 29.

Departments of Medicine and Surgery, Columbia University, 622 West 168th Street, PH-14, room 105 C, New York, NY, 10032, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-015-0155-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4469402PMC
May 2015